Comparison of six cycles of epirubicin and paclitaxel (ET) versus four cycles of epirubicin and cyclophosphamide, followed by four cycles of paclitaxel (EC-T) as adjuvant therapy for operable breast cancer in women with positive axillary nodes

被引：0
|
作者：
Yuan, Peng
Wang, Jiayu
Ma, Fei
Fan, Ying
Luo, Yang
Cai, Ruigang
Zhang, Pin
Li, Qing
Xu, Binghe
机构：
[1] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing 100730, Peoples R China
[2] Peking Union Med Coll, Beijing 100021, Peoples R China
[3] Chinese Acad Med Sci, Canc Hosp & Inst, Beijing 100730, Peoples R China
[4] Chinese Acad Med, Canc Hosp Inst, Dept Med Oncol, Beijing, Peoples R China
[5] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.1042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comparison of doxorubicin and cyclophosphamide (AC) versus single-agent paclitaxel (T) as adjuvant therapy for breast cancer in women with 0-3 positive axillary nodes: CALGB 40101
    Shulman, Lawrence N.
    Berry, Donald A.
    Cirrincione, Constance T.
    Becker, Heather
    Perez, Edith A.
    O'Regan, Ruth
    Martino, Silvana
    Shapiro, Charles L.
    Atkins, James
    Schneider, Charles
    Kimmick, Gretchen Genevieve
    Burstein, Harold J.
    Norton, Larry
    Musa, Hyman Bernard
    Hudis, Clifford
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)
    Shulman, Lawrence N.
    Berry, Donald A.
    Cirrincione, Constance T.
    Becker, Heather P.
    Perez, Edith A.
    O'Regan, Ruth
    Martino, Silvana
    Shapiro, Charles L.
    Schneider, Charles J.
    Kimmick, Gretchen
    Burstein, Harold J.
    Norton, Larry
    Muss, Hyman
    Hudis, Clifford A.
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (22) : 2311 - U184
  • [23] Comparison of Doxorubicin and Cyclophosphamide Versus Single-Agent Paclitaxel As Adjuvant Therapy for Breast Cancer in Women With 0 to 3 Positive Axillary Nodes: CALGB 40101 (Alliance)
    Shih, J. Y.
    Goldstein, L. J.
    Breast Diseases, 2015, 26 (01): : 83 - 84
  • [24] OPERABLE BREAST-CANCER WITH POSITIVE AXILLARY NODES (N+) - RESULTS OF 6 VS 12 CYCLES OF ADJUVANT CMF IN PREMENOPAUSAL WOMEN
    TANCINI, G
    BAJETTA, E
    MARCHINI, S
    VALAGUSSA, P
    BONADONNA, G
    VERONESI, U
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 172 - 172
  • [25] What is the ideal duration of adjuvant therapy for primary breast cancer: are four cycles of cyclophosphamide and doxorubicin enough?
    Shulman L.N.
    Current Oncology Reports, 2001, 3 (6) : 523 - 528
  • [26] Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes
    Battelli, Nicola
    Massacesi, Cristian
    Braconi, Chiara
    Pilone, Alberta
    Manzione, Luigi
    Dinota, Angelo
    Cobelli, Stefano
    Scanni, Alberto
    Sturba, Fabio
    Giacomini, Giusi
    Morale, Donatella
    Giorgi, Francesca
    Tummarello, Diego
    Cascinu, Stefano
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 380 - 384
  • [27] Epirubicin and cyclophosphamide (EC) followed by weekly paclitaxel with/without trastuzumab as primary systemic therapy in locally advanced breast cancer: Phase II study
    Hirano, A.
    Shimizu, T.
    Kamimura, M.
    Goto, N.
    Watanabe, O.
    Kinoshita, J.
    Domoto, K.
    Aiba, M.
    Ogawa, K.
    Miura, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [28] Benefit of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide (CEX) versus 5-FU + epirubicin plus cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)
    Berton-Rigaud, D.
    Roche, H.
    Penault-Llorca, F.
    Tubiana-Mathieu, N.
    Ferrero, J.
    Coudert, B.
    Milano, G. A.
    Mousseau, M.
    Homokos, H.
    Fumoleau, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Comparison of overall and recurrence-free survival between four and six cycles of adjuvant docetaxel and cyclophosphamide in early stage breast cancer
    Mehmi, I.
    Wight, C. E.
    Hill, J. L.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] A multicenter phase II study of preoperative epirubicin, cyclophosphamide (EC) followed by paclitaxel (P) plus trastuzumab (T) in Her2 positive primary breast cancer
    Untch, M
    Stoeckl, D
    Konecny, G
    Kreienberg, R
    Thommsen, C
    Camara, O
    Moebus, V
    Kuehn, T
    DuBois, A
    Lueck, HJ
    Gitsch, G
    Fasching, P
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S60 - S61
12345